Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.

MLA

Finazzi, Maria Chiara, et al. “Rituximab Added to Conditioning Regimen Significantly Improves Erythroid Engraftment in Major Incompatible ABO-Group Hematopoietic Stem Cell Transplantation.” Bone Marrow Transplantation, vol. 59, no. 6, June 2024, pp. 751–58. EBSCOhost, https://doi.org/10.1038/s41409-024-02247-w.

APA

Finazzi, M. C., Weber, A., Pavoni, C., Grassi, A., Micò, M. C., Algarotti, A., Lussana, F., & Rambaldi, A. (2024). Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation. Bone Marrow Transplantation, 59(6), 751–758. https://doi.org/10.1038/s41409-024-02247-w

Chicago

Finazzi, Maria Chiara, Alessandra Weber, Chiara Pavoni, Anna Grassi, Maria Caterina Micò, Alessandra Algarotti, Federico Lussana, and Alessandro Rambaldi. 2024. “Rituximab Added to Conditioning Regimen Significantly Improves Erythroid Engraftment in Major Incompatible ABO-Group Hematopoietic Stem Cell Transplantation.” Bone Marrow Transplantation 59 (6): 751–58. doi:10.1038/s41409-024-02247-w.